1. Home
  2. KPLT vs SCLX Comparison

KPLT vs SCLX Comparison

Compare KPLT & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Katapult Holdings Inc.

KPLT

Katapult Holdings Inc.

HOLD

Current Price

$9.46

Market Cap

39.2M

ML Signal

HOLD

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$5.11

Market Cap

35.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KPLT
SCLX
Founded
2012
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.2M
35.2M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
KPLT
SCLX
Price
$9.46
$5.11
Analyst Decision
Hold
Analyst Count
1
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
129.4K
33.0K
Earning Date
05-07-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
98.15
N/A
EPS
N/A
N/A
Revenue
$291,761,000.00
$30,253,000.00
Revenue This Year
$18.62
$122.52
Revenue Next Year
$15.34
$186.30
P/E Ratio
N/A
N/A
Revenue Growth
18.03
N/A
52 Week Low
$5.30
$4.20
52 Week High
$19.68
$34.27

Technical Indicators

Market Signals
Indicator
KPLT
SCLX
Relative Strength Index (RSI) 68.95 38.69
Support Level $6.05 $4.20
Resistance Level $9.21 $7.77
Average True Range (ATR) 0.74 0.28
MACD 0.21 0.06
Stochastic Oscillator 90.21 40.23

Price Performance

Historical Comparison
KPLT
SCLX

About KPLT Katapult Holdings Inc.

Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Share on Social Networks: